ATAD2 is expressed in androgen-dependent and androgen-sensitive prostate cancer (PC) cells in response to androgen stimulation, and its levels are further elevated in androgen-independent and hormone-refractory PC cells. The gene discussed is ATAD2; the disease is pachyonychia congenita.